A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

NCT ID: NCT04643457

Last Updated: 2025-09-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 107 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-27
• Study Completion Date: 2024-06-06

Brief Summary

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or subcutaneous injection to healthy study participants and following repeat dosing at a single dose level in study participants with atopic dermatitis. Furthermore, the clinical efficacy outcome in study participants with atopic dermatitis after administration of UCB9741 by intravenous infusion will be investigated.

Conditions

Atopic Dermatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Part A: Intravenous UCB9741 arm 1

Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

Group Type: EXPERIMENTAL

UCB9741

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Part A: Intravenous UCB9741 arm 2

Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

Group Type: EXPERIMENTAL

UCB9741

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Part A: Intravenous UCB9741 arm 3

Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

Group Type: EXPERIMENTAL

UCB9741

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Part A: Intravenous UCB9741 arm 4

Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

Group Type: EXPERIMENTAL

UCB9741

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Part A: Intravenous UCB9741 arm 5

Subjects randomized to this arm will receive a pre-specified single intravenous dose of UCB9741.

Group Type: EXPERIMENTAL

UCB9741

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Part A: Subcutaneous UCB9741 arm 1

Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.

Group Type: EXPERIMENTAL

UCB9741

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Part A: Subcutaneous UCB9741 arm 2

Subjects randomized to this arm will receive a pre-specified single subcutaneous dose of UCB9741.

Group Type: EXPERIMENTAL

UCB9741

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Part A: Intravenous Placebo arm

Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.

Group Type: PLACEBO_COMPARATOR

Intravenous Placebo

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.

Part A: Subcutaneous Placebo arm

Subjects randomized to this arm will receive subcutaneous Placebo to maintain the blinding.

Group Type: PLACEBO_COMPARATOR

Subcutaneous Placebo

Intervention Type: DRUG

Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.

Part B: Intravenous UCB9741 arm

Subjects randomized to this arm will receive pre-specified intravenous doses of UCB9741.

Group Type: EXPERIMENTAL

UCB9741

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Part B: Intravenous Placebo arm

Subjects randomized to this arm will receive intravenous Placebo to maintain the blinding.

Group Type: PLACEBO_COMPARATOR

Intravenous Placebo

Intervention Type: DRUG

\- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.

Interventions

UCB9741

\- Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention Type: DRUG

Intravenous Placebo

\- Pharmaceutical form: Solution Participants will receive Placebo to maintain the blinding during the Treatment Period.

Intervention Type: DRUG

Subcutaneous Placebo

Pharmaceutical form: Solution Participants will receive subcutaneous Placebo to maintain the blinding during the Treatment Period.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Part A:

• Participant must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF)
• Participant must be overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
• Participant has a body mass index (BMI) within the range 18 to 30 kg/m^2 (inclusive)
• Participant can be male or female

• A male participant must agree to use contraception during the Treatment Period and for at least 90 days after the final dose of investigational medicinal product (IMP), and refrain from donating sperm during this period
• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 90 days after the final dose of IMP

Part B:

• Participant must be 18 to 65 years of age inclusive at the time of signing the ICF
• Participant has a documented history of moderate or severe atopic dermatitis (AtD) that has been present for at least 12 months prior to initiating the study (signing of the ICF) and with:

• validated Investigator Global Assessment (vIGA) score ≥3 at Screening (Visit 1) and Baseline (Visit 2)
• Eczema Area and Severity Index (EASI) score of ≥14 at Screening (Visit 1) and ≥16 at Baseline (Visit 2)
• Pruritus Numerical Rating Scale (NRS) score ≥ 3 at Screening (Visit 1) and Baseline (Visit 2)
• ≥10% body surface area (BSA) of AtD involvement at Screening (Visit 1) and Baseline (Visit 2)
• Either documented recent history (within 6 months before the Screening Visit) of inadequate response to treatment with topical medications (regular use of topical corticosteroids [TCS] or topical calcineurin inhibitors [TCIs]) or when topical treatments are confirmed to be otherwise medically inadvisable (eg, because of important side effects or safety risks). Inadequate response is defined as failure to achieve and maintain remission or low disease remission or a low disease activity state (validated Investigator Global Assessment (vIGA) 0=clear to vIGA 2=mild) despite treatment with a daily regimen of TCS of medium to higher potency (±TCI as appropriate), applied for at least 4 weeks or for the maximum duration recommended by the product prescribing information (eg, 2 weeks for high potency TCS), whichever is shorter
• Participant has a body mass index (BMI) within the range 18 to 32 kg/m^2 (inclusive)
• Participant can be male or female
• A male participant must agree to use contraception during the Treatment Period and for at least 60 days after the final dose of IMP, and refrain from donating sperm during this period
• A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 60 days after the final dose of IMP

Exclusion Criteria

Part A:

• Participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) or other biologic drugs as stated in this protocol
• Participant has a significant allergy to humanized monoclonal antibodies (mAbs)
• Participant has clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions
• Participant has abnormal blood pressure (BP) (outside the normal range) in a supine position after 5 minutes rest
• Participant has alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) >1.0x upper limit of normal (ULN)
• Participant has a recent history or currently active clinically-significant bacterial, fungal, endoparasite, or viral (including hospitalization for coronavirus disease 2019 (COVID-19)) infection (within 6 months of the Screening Visit)
• Participant has a history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
• Participant has a history of diabetes
• Participant has a corrected QT interval (QTc) >450 msec
• Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits), within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives (oral, implants, or intrauterine devices) or occasional use of analgesics, such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4 g/day and 10 g/14 days)
• Participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or within 90 days after the final dose of IMP
• Participant has been treated with biologic agents (such as mAbs, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the Baseline Visit
• Participant has participated in another study of an IMP within the previous 90 days or 5 half-lives of the IMP (whichever longer), or is currently participating in another study of an IMP
• Participant has sensitivity to heparin or heparin-induced thrombocytopenia

Part B:

• Participant has a known hypersensitivity to any components of the IMP or other biologic drugs as stated in this protocol
• Participant has significant allergies to humanized mAbs
• Participant has clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
• Participant has abnormal BP (outside the normal range) in a supine position after 5 minutes rest
• Participant has ALT, AST, or ALP >1.5xULN
• Participant has a recent history of or clinically active clinically-significant, as judged by the Investigator, bacterial, fungal, endoparasite, or viral (or any history of hospitalization for COVID-19) infection (within 6 months of the Screening Visit)
• Participant has a history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
• Participant has a history of diabetes that is not well controlled with diet
• Participant has a mean QT interval (QTc) >450 msec for male study participants or >470 msec for female study participants
• Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits) within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives (oral, implants, or intrauterine devices) or occasional use of analgesics such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4 g/day and 10 g/14 days) or intranasal corticosteroids for seasonal rhinitis or inhaled bronchodilators and low dose inhaled corticosteroids for mild asthma
• Participant has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the Baseline Visit or is anticipated to do so within 60 days after the final dose of IMP
• Participant has been treated with biologic agents (such as mAbs, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the Baseline Visit
• Participant has participated in another study of an IMP within the previous 30 days or 5 half-lives of IMP (whichever longer) from the Baseline Visit or is currently participating in another study of an IMP
• Participant has sensitivity to heparin or heparin-induced thrombocytopenia

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

UCB Biopharma SRL

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

UCB Cares

Role: STUDY_DIRECTOR

001 844 599 2273 (UCB)

Locations

Up0089 303

Pleven, , Bulgaria

Up0089 301

Sofia, , Bulgaria

Up0089 304

Sofia, , Bulgaria

Up0089 407

Berlin, , Germany

Up0089 408

Heidelberg, , Germany

Up0089 410

Leipzig, , Germany

Up0089 201

Leiden, , Netherlands

Up0089 104

Liverpool, , United Kingdom

Up0089 101

London, , United Kingdom

Up0089 103

Manchester, , United Kingdom

Countries

Bulgaria; Germany; Netherlands; United Kingdom

Other Identifiers

2020-003639-41

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

UP0089

Identifier Type: -

Identifier Source: org_study_id